Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells

References

• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105–11; PMID:11689955; http://dx.doi.org/10.1038/35102167
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008; 75:75–84; PMID:18544962; http://dx.doi.org/10.1159/000123845
   PubMed Web of Science ®Google Scholar
• Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64:937–46; PMID:21680574; http://dx.doi.org/10.1136/jcp.2011.090456
   PubMed Web of Science ®Google Scholar
• Velasco-Velazquez MA, Popov VM, Lisanti MP, Pestell RG. The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol 2011; 179:2–11; PMID:21640330; http://dx.doi.org/10.1016/j.ajpath.2011.03.005
   PubMed Web of Science ®Google Scholar
• Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surgical Oncol 2010; 19:27–32; PMID:19251410; http://dx.doi.org/10.1016/j.suronc.2009.01.004
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44(+) breast cancer-initiating cells to radiation. J Natl Cancer I 2006; 98:1777–85; PMID:17179479
   PubMed Web of Science ®Google Scholar
• Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012; 2012:708036; PMID:22693526; http://dx.doi.org/10.1155/2012/708036
   PubMedGoogle Scholar
• Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66:9339–44; PMID:16990346; http://dx.doi.org/10.1158/0008-5472.CAN-06-3126
   PubMedGoogle Scholar
• Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, Los M. Cancer stem cell markers in common cancers - therapeutic implications. Trend Mol Med 2008; 14:450–60; PMID:18775674; http://dx.doi.org/10.1016/j.molmed.2008.08.003
   PubMed Web of Science ®Google Scholar
• Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest J Tech Method Pathol 2009; 89:857–66; PMID:19488035; http://dx.doi.org/10.1038/labinvest.2009.54
   PubMed Web of Science ®Google Scholar
• Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimaki A, Virkkunen P, Tarkkanen M, et al. Tissue-specific promoters active in CD44+CD24−/low breast cancer cells. Cancer Res 2008; 68:5533–9; PMID:18632604; http://dx.doi.org/10.1158/0008-5472.CAN-07-5288
   PubMed Web of Science ®Google Scholar
• Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11:1154–9; PMID:15709183
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101:14228–33; PMID:15381773; http://dx.doi.org/10.1073/pnas.0400067101
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555–67; PMID:18371393; http://dx.doi.org/10.1016/j.stem.2007.08.014
   PubMed Web of Science ®Google Scholar
• Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140:62–73; PMID:20074520; http://dx.doi.org/10.1016/j.cell.2009.12.007
   PubMed Web of Science ®Google Scholar
• Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147:759–72; PMID:22078877; http://dx.doi.org/10.1016/j.cell.2011.09.048
   PubMed Web of Science ®Google Scholar
• Wang X, Cao LEI, Wang Y, Wang X, Liu N, You Y. Regulation of let-7 and its target oncogenes (Review). 2012; 955–60; PMID:22783372
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215–33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
   PubMed Web of Science ®Google Scholar
• Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315:1576–9; PMID:17322030; http://dx.doi.org/10.1126/science.1137999
   PubMed Web of Science ®Google Scholar
• Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Gene Dev 2009; 23:1743–8; PMID:19574298; http://dx.doi.org/10.1101/gad.1812509
   PubMed Web of Science ®Google Scholar
• Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, Recker RR, Gatalica Z, Wang Z, Xiao GG. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Mol Med 2011; 17:1233–41; PMID:21826373; http://dx.doi.org/10.2119/molmed.2010.00225
   PubMedGoogle Scholar
• Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, Wood W 3rd, Becker KG, Morin PJ. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PloS one 2008; 3:e2436; PMID:18560586; http://dx.doi.org/10.1371/journal.pone.0002436
   PubMed Web of Science ®Google Scholar
• Yu Z, Li Y, Fan H, Liu Z, Pestell RG. miRNAs regulate stem cell self-renewal and differentiation. Frontier Genet 2012; 3:191; PMID:23056008; http://dx.doi.org/10.3389/fgene.2012.00191
   PubMedGoogle Scholar
• Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109–23; PMID:18083101; http://dx.doi.org/10.1016/j.cell.2007.10.054
   PubMed Web of Science ®Google Scholar
• Zamkova M, Khromova N, Kopnin BP, Kopnin P. Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSF1/SESN3/p21Cip1/WAF1 pathways. Cell Cycle 2013; 12:826–36; PMID:23388456; http://dx.doi.org/10.4161/cc.23723
   PubMed Web of Science ®Google Scholar
• Takahashi C, Bronson RT, Socolovsky M, Contreras B, Lee KY, Jacks T, Noda M, Kucherlapati R, Ewen ME. Rb and N-ras function together to control differentiation in the mouse. Mol Cell Biol 2003; 23:5256–68; PMID:12861012; http://dx.doi.org/10.1128/MCB.23.15.5256-5268.2003
   PubMed Web of Science ®Google Scholar
• Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. Intl J Cancer 2013; 133:43–57; PMID:23280667; http://dx.doi.org/10.1002/ijc.28001
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635–47; PMID:15766527; http://dx.doi.org/10.1016/j.cell.2005.01.014
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu J, Ghosh G. KappaB-Ras binds to the unique insert within the ankyrin repeat domain of IkappaBbeta and regulates cytoplasmic retention of IkappaBbeta × NF-kappaB complexes. J Biol Chem 2003; 278:23101–6; PMID:12672800; http://dx.doi.org/10.1074/jbc.M301021200
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139:693–706; PMID:19878981; http://dx.doi.org/10.1016/j.cell.2009.10.014
   PubMed Web of Science ®Google Scholar
• Hinohara K, Kobayashi S, Kanauchi H, Shimizu S, Nishioka K, Tsuji E, Tada K, Umezawa K, Mori M, Ogawa T, et al. ErbB receptor tyrosine kinase/NF-kappaB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A 2012; 109:6584–9; PMID:22492965; http://dx.doi.org/10.1073/pnas.1113271109
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291–310; PMID:17496923; http://dx.doi.org/10.1038/sj.onc.1210422
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Biophys Acta 2007; 1773:1263–84; PMID:17126425; http://dx.doi.org/10.1016/j.bbamcr.2006.10.001
   PubMed Web of Science ®Google Scholar
• Choudhury SN, Li Y. miR-21 and let-7 in the Ras and NF-κB Pathways. MicroRNA 2012; 1:65–9; PMID:25048092; http://dx.doi.org/10.2174/2211536611201010065
   PubMedGoogle Scholar
• Bonini SA, Ferrari-Toninelli G, Uberti D, Montinaro M, Buizza L, Lanni C, Grilli M, Memo M. Nuclear factor kappaB-dependent neurite remodeling is mediated by Notch pathway. J Neuroscience 2011; 31:11697–705; PMID:21832199; http://dx.doi.org/10.1523/JNEUROSCI.1113-11.2011
   PubMed Web of Science ®Google Scholar
• Bravo SB, Pampin S, Cameselle-Teijeiro J, Carneiro C, Dominguez F, Barreiro F, Alvarez CV. TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-kappaB activation. Oncogene 2003; 22:7819–30; PMID:14586408; http://dx.doi.org/10.1038/sj.onc.1207029
   PubMed Web of Science ®Google Scholar
• Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Gene Dev 2003; 17:1253–70; PMID:12756227; http://dx.doi.org/10.1101/gad.1061803
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645–59; PMID:19682730; http://dx.doi.org/10.1016/j.cell.2009.06.034
   PubMed Web of Science ®Google Scholar
• Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, Lopez JA. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 2008; 10:210; PMID:18671830; http://dx.doi.org/10.1186/bcr2111
   PubMed Web of Science ®Google Scholar
• Ding XC, Slack FJ, Großhans H. The let-7 microRNA interfaces extensively with the translation machinery to regulate cell differentiation. Cell cycle (Georgetown, Tex) 2008; 7:3083–90.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834–8; PMID:15944708; http://dx.doi.org/10.1038/nature03702
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature reviews Genetics 2009; 10:704–14; PMID:19763153; http://dx.doi.org/10.1038/nrg2634
   PubMed Web of Science ®Google Scholar
• Whitmarsh AJ. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochimica Biophy Acta 2007; 1773:1285–98; PMID:17196680; http://dx.doi.org/10.1016/j.bbamcr.2006.11.011
   PubMed Web of Science ®Google Scholar
• Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68:320–44; PMID:15187187; http://dx.doi.org/10.1128/MMBR.68.2.320-344.2004
   PubMed Web of Science ®Google Scholar
• Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011; 3:192–222; PMID:21422497
   PubMedGoogle Scholar
• Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, Lessard F, Moiseeva O, Forest V, Igelmann S, Mallette FA, Saba-El-Leil MK, Meloche S, et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Gene Dev 2013; 27:900–15; PMID:23599344; http://dx.doi.org/10.1101/gad.203984.112
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion Therapeutic Targets 2012; 16:103–19; PMID:22239440; http://dx.doi.org/10.1517/14728222.2011.645805
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64:3753–6; PMID:15172979; http://dx.doi.org/10.1158/0008-5472.CAN-04-0637
   PubMed Web of Science ®Google Scholar
• Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15:489–500; PMID:19477428; http://dx.doi.org/10.1016/j.ccr.2009.03.022
   PubMed Web of Science ®Google Scholar
• Kwon O, Jeong SJ, Kim SO, He L, Lee HG, Jang KL, Osada H, Jung M, Kim BY, Ahn JS. Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b. Carcinogenesis 2010; 31:1194–201; PMID:20375073
   PubMed Web of Science ®Google Scholar
• Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res 2007; 67:7139–46; PMID:17671181; http://dx.doi.org/10.1158/0008-5472.CAN-07-0778
   PubMed Web of Science ®Google Scholar
• Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 2013; 32:5272–82; PMID:23318420; http://dx.doi.org/10.1038/onc.2012.573
   PubMed Web of Science ®Google Scholar
• Wang XR, Luo H, Li HL, Cao L, Wang XF, Yan W, Wang YY, Zhang JX, Jiang T, Kang CS, et al. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro-Oncol 2013; 15:1491–501; PMID:24092860; http://dx.doi.org/10.1093/neuonc/not107
   PubMed Web of Science ®Google Scholar
• Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011; 71:7226–37; PMID:21900397; http://dx.doi.org/10.1158/0008-5472.CAN-10-4660
   PubMed Web of Science ®Google Scholar
• Wang T, Liu Z, Guo S, Wu L, Li M, Yang J, Chen R, Xu H, Cai S, Chen H, et al. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget 2014; 5:3611–21; PMID:25003983
   PubMed Web of Science ®Google Scholar
• Wang T, Guo SM, Liu Z, Wu LC, Li MC, Yang J, Chen RB, Liu XM, Xu H, Cai SX, et al. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget 2014; 5:10293–306; PMID:25296973
   PubMed Web of Science ®Google Scholar
• Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer 2014; 6:1–13; PMID:24648765; http://dx.doi.org/10.2147/BCTT.S37638
   PubMedGoogle Scholar